RecruitingNCT05804331
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
Sponsor
Western Sydney Local Health District
Enrollment
500 participants
Start Date
Mar 14, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This multicenter Australian and New Zealand study is collecting data on outcomes of advanced endoscopic procedures — including endoscopic submucosal dissection (ESD), full-thickness resection (EFTR), and submucosal tunneling resection (STER) — used to remove tumors or abnormal growths in the upper digestive tract (esophagus, stomach, and duodenum).
**You may be eligible if:**
- You are 18 or older
- You have a growth or lesion in the upper digestive tract (esophagus, stomach, or duodenum) larger than 10mm
- The lesion is confined to the inner layers of the gut wall (suitable for one of the listed endoscopic procedures)
**You may NOT be eligible if:**
- You are under 18
- You are unable to give informed consent
- You are pregnant or breastfeeding
- You have a bleeding disorder or cannot safely stop blood-thinning medications before the procedure
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05804331
Related Trials
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
NCT045579691 location
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
NCT0595736725 locations
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT0646994450 locations
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT0644597244 locations
PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER
NCT071788081 location